GlassScriptPhysician profile
Yuhan Gu
NPI 1821612318
$1,353.85
in general payments reported to CMS, 2019-2025
16 companies · $841 in 2025
The $841 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $513 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.86 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $241.61 | 2024-2025 | |
| Janssen Biotech, INC. | $143.71 | 2024-2025 | Tremfya |
| Abbvie INC. | $141.37 | 2025 | |
| Ucb, INC. | $126.57 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $110.87 | 2024-2025 | |
| Leo Pharma INC. | $102.39 | 2024-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $79.92 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $63.76 | 2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $63.51 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $55.19 | 2025 | |
| Incyte Corporation | $53.36 | 2024-2025 | Opzelura |
| Amgen INC. | $50.08 | 2024-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.18 | 2024-2025 | Spevigo |
| Organon LLC | $36.23 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $23.36 | 2025 | Nemluvio |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $18.74 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuhan Gu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.